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Optical imaging techniques have emerged as a possible alternative 
to predict pathological complete response (pCR) in breast cancer 
patients undergoing neoadjuvant chemotherapy (NAC). Our team 
developed a so-called diffuse optical tomographic breast imaging 
system (DOTBIS) which does not require the use of contrast agents 
or compression, and enables imaging of the whole breast volume 
using low intensity near infrared light capable to measure tissue 
concentration of oxy-hemoglobin (ctO2Hb), deoxy-hemoglobin 
(ctHHb) and water percentage. In this retrospective study, ctTHb 
changes in the tumor region of 16 breast cancer patients were 
analyzed across NAC. Both breasts of all patients have been 
scanned simultaneously with our DOTBIS system, Figure 1, which 
employs four wavelengths and gathers data from a total of 64 
sources and 128 detectors per breast. A PDE-constrained 
multispectral image reconstruction code creates 3D image maps of 
total hemoglobin (ctHbT = ctO2Hb+ ctHHb). Tumor volume is selected by entering radiologic information such 
as tumor side, clock position and distance from the nipple (FN).  An automated code was designed to select the 
highest value from the distance FN and the quadrant 
referent to the clock position. Subsequently, a region-
based image segmentation method is implemented to 
examine neighboring pixels of the highest value point 
considering a mask of 90%. After tumor volume 
segmentation, we calculate the mean ctHbT extracted 
from the region of interest. An independent-samples t-
test was run to determine if there were differences in 
ctTHb reduction in the tumor region before the third 
cycle of taxane between responders (n=4) and non-
responders (n=12). ctTHb reduction was greater to pCR 
(45.71 ± 25.16 M) than non-pCR tumors (-9.67 ± 25.65 
M), a statistically significant difference of 55.38 M 
(95% CI, 23.74 to 87), t(14) = 3.755, p = .002, in Figure 
2 we can see an example. From the ROC plot results, 
we can observe that ctTHb reduction in the tumor region 
after 2 cycles of Taxane is a good indicator to anticipate 
pCR status. With an area under the curve of 0.958, the 
best cut-off that maximizes sensitivity and specificity is 
16.86M. At this reduction level, the sensitivity is 100% 
and specificity is 91.7%. In conclusion, our findings 
indicate that DOTBIS-measured total hemoglobin in the 
tumor region may be a strong and independent predictor 
of treatment response to NAC. 
 
Figure 1 – Photograph of the custom-
built diffuse optical tomographic breast 
imaging system (DOTBIS). 
Figure 2 – Comparison between a pCR and non-pCR 
patient at baseline and before the third cycle of 
taxane. We see a significant reduction in ctTHb right 
after the second taxane drug cycle in the tumor region 
(filled circle line) for the pCR patient. Nipple region is 
identified by the dashed circle line.   
